A comparison of two drugs used in patients with high cholesterol levels

Comparative study of Atorvastatin and Rosuvastatin in combination with Fenofibrate in Hyperlipidemics

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/11/005169

Enrollment

100

Registered

2014-11-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Hyperlipidemia

Interventions

Intervention1: Atorvastatin and Fenofibrate: Atorvastatin 10 mg and Fenofibrate 160 mg orally once daily for 12 weeks Control Intervention1: Rosuvastatin and Fenofibrate: Rosuvastatin 10 mg and Fenofi

Eligibility

Inclusion criteria

Inclusion criteria: 1. Low density lipoprotein cholesterol (LDL-C) higher than130 mg/dl 2. Triglycerides (TG) more than 250 mg/dl will be included in the study. Patient with 3. Hypertension 4. Diabetes mellitus 5. Obesity and 6. Coronary artery disease will be included in the study.

Exclusion criteria

Exclusion criteria: Patients with 1. Renal and hepatic failure 2. Pregnancy 3. Hypothyroidism 4. Malignancy 5. Myopathy 6. Patients who had undergone bypass surgery, and 7. Patients who are taking cardiac drugs like warfarin, verapamil and amiodarone will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
Reduction in LDL Cholesterol, Triglyceride levels, VLDL Increase in HDL levelsTimepoint: 1. Baseline visit 2. After 3 months of treatment with study medications	—

Secondary

Measure	Time frame
overall improvement in health conditionTimepoint: baseline and 3 months	—

Countries

India

Contacts

Public ContactDrTJayasree

mamata medical college

drtjayasreemd@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026